MC10, Inc., the company pioneering conformal, body-worn computing systems, is excited to announce the successful completion of their innovative collaboration with global biopharmaceutical company UCB, investigating the application of wearable, ambulatory sensors in providing clinical grade Parkinson’s Disease data.

This study is the first and most comprehensive of its kind between a wearable technology company and a major pharmaceutical company.

The results of the study, targeted for scientific publication, represent the culmination of over two and a half years of partnership between UCB and MC10.MC10’s core mission of leveraging our unique technology to improve the understanding of human health and wellness is well aligned to UCB’s commitment to patient-centered care,” commented Scott Pomerantz, MC10’s Chief Executive Officer.

Our collaboration with UCB has allowed us to grow as a company by better understanding the needs of patients and the pharmaceutical industry’s efforts and approaches to meeting their needs.” The study assessed the feasibility of monitoring Parkinson’s Disease patients in clinic and home settings while wearing sensors built with MC10’s unique epidermal electronics platform.

In addition to data recorded from the wearable sensors, researchers collected neurological assessments from trained clinicians and patient reported outcomes.